JP2012505912A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012505912A5 JP2012505912A5 JP2011532250A JP2011532250A JP2012505912A5 JP 2012505912 A5 JP2012505912 A5 JP 2012505912A5 JP 2011532250 A JP2011532250 A JP 2011532250A JP 2011532250 A JP2011532250 A JP 2011532250A JP 2012505912 A5 JP2012505912 A5 JP 2012505912A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- fgfr
- sequence
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000917148 Homo sapiens Fibroblast growth factor receptor 3 Proteins 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 4
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims 3
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000002860 competitive effect Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 238000012286 ELISA Assay Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19685508P | 2008-10-20 | 2008-10-20 | |
| US61/196,855 | 2008-10-20 | ||
| PCT/US2009/060840 WO2010048026A2 (en) | 2008-10-20 | 2009-10-15 | Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012505912A JP2012505912A (ja) | 2012-03-08 |
| JP2012505912A5 true JP2012505912A5 (enExample) | 2014-04-03 |
| JP5577345B2 JP5577345B2 (ja) | 2014-08-20 |
Family
ID=42062445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011532250A Expired - Fee Related JP5577345B2 (ja) | 2008-10-20 | 2009-10-15 | 線維芽細胞成長因子受容体３（ｆｇｆｒ−３）阻害剤および治療方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US8043618B2 (enExample) |
| EP (1) | EP2342232A2 (enExample) |
| JP (1) | JP5577345B2 (enExample) |
| KR (1) | KR101370798B1 (enExample) |
| CN (2) | CN102186884B (enExample) |
| AR (1) | AR073770A1 (enExample) |
| AU (1) | AU2009307841B2 (enExample) |
| BR (1) | BRPI0919832A8 (enExample) |
| CA (1) | CA2741127C (enExample) |
| EA (1) | EA021584B1 (enExample) |
| IL (1) | IL211807A0 (enExample) |
| MX (1) | MX2011004317A (enExample) |
| NZ (1) | NZ592369A (enExample) |
| TW (1) | TWI381848B (enExample) |
| UA (1) | UA101681C2 (enExample) |
| WO (1) | WO2010048026A2 (enExample) |
| ZA (1) | ZA201101938B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR073770A1 (es) | 2008-10-20 | 2010-12-01 | Imclone Llc | Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden |
| DK3702371T5 (da) | 2009-03-25 | 2024-08-26 | Genentech Inc | Anti-FGFR3-antistoffer og fremgangsmåder ved anvendelse af disse |
| WO2013088191A1 (en) | 2011-12-12 | 2013-06-20 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3 |
| WO2014111744A1 (en) | 2013-01-16 | 2014-07-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders |
| MX2015011428A (es) | 2013-03-06 | 2016-02-03 | Genentech Inc | Metodos para tratar y prevenir la resistencia a los farmacos para el cancer. |
| TWI541022B (zh) | 2013-12-18 | 2016-07-11 | 應克隆公司 | 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法 |
| EP3122776B1 (en) | 2014-03-25 | 2021-04-28 | Regeneron Pharmaceuticals, Inc. | Fgf21 receptor agonists and uses thereof |
| EP3151857A4 (en) * | 2014-06-03 | 2018-04-18 | Merck Sharp & Dohme Corp. | Anti-blys antibodies |
| CN107073121A (zh) | 2014-06-13 | 2017-08-18 | 基因泰克公司 | 治疗及预防癌症药物抗性的方法 |
| MX384149B (es) * | 2014-09-05 | 2025-03-14 | Hyperfine Inc | Aumento ferromagnético para formación de imagenes por resonancia magnética. |
| KR102470456B1 (ko) | 2014-09-26 | 2022-11-23 | 얀센 파마슈티카 엔.브이. | Fgfr 억제제를 사용한 치료에 반응할 암 환자를 확인하는 데 있어서 fgfr 돌연변이 유전자 패널의 사용 |
| SG11201706727XA (en) * | 2015-02-19 | 2017-09-28 | Bioclin Therapeutics Inc | Methods, compositions, and kits for treatment of cancer |
| US20180237424A1 (en) | 2015-03-03 | 2018-08-23 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Fgfr3 antagonists |
| TW201711702A (zh) | 2015-06-04 | 2017-04-01 | 應克隆公司 | 使用針對纖維母細胞生長因子受體３（ｆｇｆｒ３）之化合物的療法 |
| WO2017100642A1 (en) | 2015-12-11 | 2017-06-15 | Regeneron Pharmaceuticals, Inc. | Methods for reducing or preventing growth of tumors resistant to egfr and/or erbb3 blockade |
| MX2018016257A (es) | 2016-07-07 | 2019-11-21 | Therachon Sas | Polipéptidos del receptor 3 del factor de crecimiento de fibroblastos solubles (sfgfr3) y usos de los mismos. |
| US20180244785A1 (en) * | 2017-01-09 | 2018-08-30 | Merrimack Pharmaceuticals, Inc. | Anti-fgfr antibodies and methods of use |
| AR123306A1 (es) | 2020-08-21 | 2022-11-16 | Genzyme Corp | Anticuerpos fgfr3 y métodos de uso |
| CN114015770B (zh) * | 2021-12-30 | 2022-04-26 | 佛山市第三人民医院(佛山市精神卫生中心) | 精神分裂全外周血rna标志物fgfr3及其应用 |
| US20240173426A1 (en) * | 2022-11-14 | 2024-05-30 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes |
| IL322053A (en) | 2023-01-13 | 2025-09-01 | Regeneron Pharma | FGFR3 binding molecules and methods of using them |
| WO2025240335A1 (en) | 2024-05-13 | 2025-11-20 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
| JP2005500034A (ja) | 2001-06-20 | 2005-01-06 | プロション バイオテク リミテッド | 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用 |
| CA2550245A1 (en) | 2003-12-19 | 2005-07-21 | Five Prime Therapeutics, Inc. | Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention |
| MX2008014978A (es) * | 2006-06-06 | 2008-12-09 | Crucell Holland Bv | Moleculas de union humanas que tienen actividad exterminadora contra enterococos y staphylococcus aureus y usos de las mismas. |
| US8192927B2 (en) * | 2006-09-07 | 2012-06-05 | Crucell Holland B.V. | Human bind molecules capable of neutralizing influenza virus h5n1 and uses thereof |
| ES2453592T3 (es) * | 2007-08-02 | 2014-04-08 | Novimmune Sa | Anticuerpos anti-RANTES y métodos de uso de los mismos |
| KR102057826B1 (ko) * | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| US8187601B2 (en) | 2008-07-01 | 2012-05-29 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (FGFR3) binding proteins |
| AR073770A1 (es) * | 2008-10-20 | 2010-12-01 | Imclone Llc | Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden |
-
2009
- 2009-10-05 AR ARP090103832A patent/AR073770A1/es unknown
- 2009-10-05 TW TW098133737A patent/TWI381848B/zh not_active IP Right Cessation
- 2009-10-15 CA CA2741127A patent/CA2741127C/en not_active Expired - Fee Related
- 2009-10-15 MX MX2011004317A patent/MX2011004317A/es active IP Right Grant
- 2009-10-15 WO PCT/US2009/060840 patent/WO2010048026A2/en not_active Ceased
- 2009-10-15 US US12/579,825 patent/US8043618B2/en not_active Expired - Fee Related
- 2009-10-15 AU AU2009307841A patent/AU2009307841B2/en not_active Ceased
- 2009-10-15 KR KR1020117008935A patent/KR101370798B1/ko not_active Expired - Fee Related
- 2009-10-15 EP EP09737319A patent/EP2342232A2/en not_active Ceased
- 2009-10-15 NZ NZ592369A patent/NZ592369A/xx not_active IP Right Cessation
- 2009-10-15 JP JP2011532250A patent/JP5577345B2/ja not_active Expired - Fee Related
- 2009-10-15 CN CN200980141656.2A patent/CN102186884B/zh not_active Expired - Fee Related
- 2009-10-15 CN CN201310384769.3A patent/CN103524620A/zh active Pending
- 2009-10-15 UA UAA201104814A patent/UA101681C2/ru unknown
- 2009-10-15 BR BRPI0919832A patent/BRPI0919832A8/pt not_active IP Right Cessation
- 2009-10-15 EA EA201170590A patent/EA021584B1/ru not_active IP Right Cessation
-
2011
- 2011-03-14 ZA ZA2011/01938A patent/ZA201101938B/en unknown
- 2011-03-17 IL IL211807A patent/IL211807A0/en unknown
- 2011-09-19 US US13/235,900 patent/US8182815B2/en not_active Expired - Fee Related
-
2012
- 2012-04-20 US US13/452,043 patent/US8404240B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012505912A5 (enExample) | ||
| IL261585A (en) | Antigen-binding human proteins that bind beta-klotho, fgf receptors and their complexes | |
| RU2747735C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| JP2020500538A5 (enExample) | ||
| WO2012045481A3 (en) | Antibody targeting osteoclast-related protein siglec-15 | |
| NZ610153A (en) | Novel anti-dr5 antibody | |
| JP2015508762A5 (enExample) | ||
| PE20170687A1 (es) | Proteinas de enlace a cd127 | |
| JP2015508763A5 (enExample) | ||
| JP2020508303A5 (enExample) | ||
| JP2013520996A5 (enExample) | ||
| JP2015522252A5 (enExample) | ||
| IL259940B2 (en) | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists | |
| JP2013517277A5 (enExample) | ||
| JP2011518125A5 (enExample) | ||
| PE20142242A1 (es) | Anticuerpos humanos anti-cd27, metodos, y usos | |
| AR086579A1 (es) | Proteinas de union a antigeno | |
| JP2012513193A5 (enExample) | ||
| PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
| PE20080262A1 (es) | Anticuerpo humanizado contra interleuquina-18 | |
| JP2017528476A5 (enExample) | ||
| JP2009106306A5 (ja) | 抗PDGFRα抗体 | |
| CL2013003140A1 (es) | Un anticuerpo monoclonal humano aislado o fragmento de union a antigeno del mismo que se une a masp-2 humana; molecula de acido nucleico, casette de expresion, celula que la expresa, metodo de produccion, composicion que la contiene, articulo que lo contiene. | |
| AR066164A1 (es) | Proteinas humanas de union a antigenos del factor estimulante de colonias de megacariocitos-macrofagos(gm-csf) | |
| JP2009511579A5 (enExample) |